Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05323487 · ClinicalTrials.gov registry record · Phase 1
Mechanisms of Diuretic Resistance in Heart Failure, Aim 1
A Phase 1 study of Heart Failure, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT05323487 is a Phase 1 study of Heart Failure that is actively recruiting participants, run by Yale University. The registered enrollment target is 75 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05323487, a Phase 1 study of Heart Failure, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will employ a randomized order, double-blind, repeated measures dose ranging design. This design was chosen in order to generate multiple within-subject serial loop diuretic dose response exposures. The overall study schema will include 75 heart failure (HF) patients.
Conditions Studied
Interventions
- DRUG Bumetanide Injection
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2026-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05323487
The ClinicalTrials.gov registry entry for NCT05323487 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (96% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Bumetanide Injection is the first listed.
NCT05323487 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT05323487 about?
NCT05323487 is a clinical study titled "Mechanisms of Diuretic Resistance in Heart Failure, Aim 1". This study will employ a randomized order, double-blind, repeated measures dose ranging design. This design was chosen in order to generate multiple within-subject serial loop diuretic dose response exposures. The overall study schema will include 75 heart failure (HF) patients.
What is the current status of trial NCT05323487?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2022-06-01. Estimated completion is 2026-11-01.
What conditions does trial NCT05323487 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT05323487?
The interventions under investigation include: Bumetanide Injection (DRUG).
Who is sponsoring clinical trial NCT05323487?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05323487 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanisms of Semaglutide Therapy in Heart Failure Patients
RECRUITING · Phase 1
-
The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)
RECRUITING · Phase 1
-
Mechanisms of Diuretic Resistance in Heart Failure, Aim 3
RECRUITING · Phase 1
-
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
RECRUITING · Phase 1
-
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
RECRUITING · Phase 1
-
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.